Rallybio (NASDAQ:RLYB) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Rallybio (NASDAQ:RLYB) announced its quarterly earnings data on Thursday. The company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.19, Zacks reports. Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.

Rallybio Stock Performance

Shares of NASDAQ RLYB traded up $0.07 during mid-day trading on Friday, hitting $16.25. The stock had a trading volume of 3,664 shares, compared to its average volume of 164,712. The business has a 50 day moving average price of $16.01 and a two-hundred day moving average price of $11.37. The firm has a market cap of $86.15 million, a P/E ratio of -3.77 and a beta of -0.90. Rallybio has a 1 year low of $3.20 and a 1 year high of $17.57.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research report on Wednesday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Insider Activity at Rallybio

In other news, major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $13.98 per share, for a total transaction of $142,596.00. Following the purchase, the insider directly owned 926,352 shares in the company, valued at $12,950,400.96. This trade represents a 1.11% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have bought 146,568 shares of company stock valued at $2,050,669. Company insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its holdings in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Citadel Advisors LLC increased its holdings in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares in the last quarter. Susquehanna International Group LLP raised its position in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the period. 90.34% of the stock is owned by hedge funds and other institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.